Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07823205) titled 'A Study to Evaluate Different Oral Formulations of KT-621' on Sept. 11.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: None (Open Label).
Primary Sponsor: Kymera Therapeutics, Inc.
Condition:
Healthy Participants
Intervention:
Drug: KT-621
Drug: KT-621
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: October 2026
Target Sample Size: 54
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07823205
Disclaimer: Curated by HT Syndication....